Page 19 - Evaluate Efficacy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article NORTH CHICAGO, Ill., April 1, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ ™ (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs). 1 These data build on previously announced Phase 3 topline results showing that upadacitinib 15 mg and 30 mg met the primary endpoint of ACR20 response at week...

Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQ™) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients - 33 percent of patients achieved the primary endpoint of clinical remission (per Adapted Mayo Score) compared to 4 percent of patients treated with placebo at week 8 (p 0.001)[1] - All ranked secondary endpoints were met[1] - These results reaffirm findings from the first Phase 3 induction study, U-ACHIEVE[1,2] - Safety results were consistent with the previous Phase 3 induction study and the known profile of upadacitinib, with no new safety ri...

ONTOZRY™ (cenobamate) receives positive CHMP opinion for the adjunctive treatment of uncontrolled focal onset seizures in adults* January 29, 2021 12:20 ET | Source: Arvelle Therapeutics Arvelle Therapeutics Positive CHMP opinion is an important milestone for Arvelle Therapeutics and cenobamate When approved, cenobamate will provide new hope in helping adult patients with uncontrolled focal epilepsy move closer to the goal of seizure reduction and seizure freedom ZUG, Switzerland, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Arvelle Therapeutics, an emerging biopharmaceutica...

European Commission Approves AbbVie's RINVOQ™ (Upadacitinib) for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis - RINVOQ (15 mg, once daily) is the first oral, once-daily, selective and reversible JAK inhibitor approved for three adult rheumatic indications in the European Union: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis[1,2] - Approval is supported by data from three pivotal clinical studies in psoriatic arthritis and ankylosing spondylitis where RINVOQ met all primary and met key secondary endpoints with a safety profile consistent with that see...

Press release content from Business Wire. The AP news staff was not involved in its creation. AriBio Co., Ltd. Announces Last Patient Last Visit in Phase 2 Clinical Trial of AR1001 in Mild to Moderate Alzheimer’s Patients January 21, 2021 GMT SEONGNAM, South Korea--(BUSINESS WIRE)--Jan 21, 2021-- AriBio Co., Ltd., a clinical-stage biopharmaceutical company based in South Korea, announced today, 21 st of January 2021, the completion of last patient last visit in a Phase 2 study of AR1001. AR1001 is a first-in-class, orally dosed investigational drug for mild to moderate Alzheimer’s disease...